



## Interrad Medical Announces Excellent New SecurAcath Clinical Data Publication and a Key Clinical Affairs Hire

Plymouth, Minn., January 29, 2014 – Interrad Medical announces a paper published in the January 23 British Journal of Nursing titled, “Peripherally Inserted Central Catheters and Minimising Migration”. The author of the paper is Meir Hughes from the Velindre Cancer Centre in Cardiff, Wales.

The highlight of the paper states that to date, the hospital team has placed 500 SecurAcath devices. The overwhelming benefit of the device is migration prevention. Not a single catheter has required replacement since their introduction. The paper goes on to emphasize the significant cost savings the SecurAcath has provided at the Velindre Cancer Centre, one of the largest cancer centres in the UK.

In addition, the Company announces the hiring of Paul Blackburn, BSN, MNA, RN, VA-BC as Vice President of Clinical Affairs. Paul has over 30 years of experience in health care in both corporate and clinical roles, including Director of Clinical Education and Marketing during 12 years at Bard Access Systems where he developed a highly successful clinical education program and managed the launch of market leading vascular access technologies. Paul speaks domestically and internationally on vascular access subjects and is the immediate past President of the Association for Vascular Access.

“Paul is a great addition to our executive team. This is an exciting time for our Company and Paul’s extensive experience and deep knowledge in vascular access will strengthen our clinical program as we accelerate SecurAcath commercialization,” commented Joe Goldberger, Interrad Medical President and CEO.

The SecurAcath subcutaneous catheter securement technology has many benefits compared to adhesive devices or sutures. SecurAcath offers a low catheter dislodgement rate which will decrease catheter replacement costs. The SecurAcath increases efficiency by decreasing the time required to secure, maintain and remove catheters. The SecurAcath lasts the life of the catheter and does not need to be replaced weekly. Its design allows for improved catheter site cleaning and minimizes catheter movement which may reduce catheter-related infections. The SecurAcath is also sutureless, therefore, eliminating the potential for costly needle stick injuries that can occur when suturing catheters.

### **About Interrad Medical, Inc.**

Plymouth, Minn.-based Interrad Medical, Inc. is a developer, manufacturer and marketer of medical devices, designed for minimally-invasive interventional and surgical procedures. The Company was founded by practicing Interventional Radiologist and Interrad Medical Chairman and Chief Medical Officer, Michael Rosenberg, M.D. For more information, visit [www.securacath.com](http://www.securacath.com).

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, reimbursement policies and commercialization of new technologies.

### **Contact:**

Jeff Killion  
Chief Marketing Officer  
Interrad Medical, Inc.  
763-225-6699  
[jeff@interradmedical.com](mailto:jeff@interradmedical.com)

181 Cheshire Lane, Suite 100  
Plymouth, MN 55441

T 763.225.6699

F 763.225.6695

[www.interradmedical.com](http://www.interradmedical.com)